Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,831 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05054985Recruiting
Stent graft for thoracoabdominal aortic aneurysm
This trial tests a specialized multi-branch stent graft to treat a large or growing aneurysm in the aorta near the chest and abdomen. It mainly looks at safety and whether the stent keeps blood flowing to important arteries.
Beijing, Beijing MunicipalityAges 18–80 - NCT05066633RecruitingPhase 3
Metoprolol added to standard care to prevent heart muscle damage
This trial tests whether adding metoprolol (a beta-blocker) to usual care can prevent or slow cardiomyopathy (heart muscle weakness) in people with Duchenne muscular dystrophy (DMD). It also checks for safety, especially effects on heart rate and rhythm.
Gdansk, Pomeranian VoivodeshipAges 8–17 - NCT05067348RecruitingPhase 2
Tocilizumab for generalized myasthenia gravis symptoms
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT05070845RecruitingPhase 2
Study drug for immune thrombocytopenia with low platelets
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
Greenville, North CarolinaAges 18–70 - NCT05071222RecruitingPhase 1/Phase 2
Gene therapy trial for Artemis SCID using modified blood cells
This trial tests whether gene therapy can safely and effectively treat children with a specific type of severe combined immunodeficiency (SCID) caused by an Artemis gene problem. It uses the patient’s own stem cells, modifies them to add a missing gene, and then returns them after chemotherapy to help the new cells work.
ParisAges Up to 3.9 years - NCT05072041Recruiting
Degradable chemo bead treatment for liver cancer
This trial studies a new type of “degradable” chemo bead delivered through a catheter to treat hepatocellular carcinoma (HCC). It aims to check safety and whether the treatment works when surgery or transplant is not an option.
Seoul, SeoulAges 19–79 - NCT05093907RecruitingPhase 1/Phase 2
Testing a new cancer drug plus capecitabine for metastatic colon cancer
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
Seoul, Jongro-goAges 19 years+ - NCT05099809Recruiting
Hyperthermia plus treatment for locally advanced cancers
This registry study looks at whether adding hyperthermia (raising body temperature) is safe and effective for people with certain locally advanced, non-spread cancers. It will follow outcomes to help doctors understand who may benefit and what side effects to expect.
Sevāgrām, MaharashtraAges 18 years+ - NCT05101551RecruitingPhase 1
Talazoparib with chemotherapy for relapsed childhood AML
This Phase 1 study tests whether talazoparib combined with chemotherapy is safe and potentially effective for children and young adults whose leukemia has come back or did not respond. It focuses on finding the best way to give the treatment and watching for side effects.
Phoenix, ArizonaAges Up to 21 years - NCT05116072RecruitingPhase 1/Phase 2
Islet cell transplant plus surgery for high fistula risk
This Phase 1/2 study tests whether adding an islet (insulin-producing cell) transplant at the time of pancreatic-region surgery is safe and helps prevent a serious surgical complication called a postoperative fistula. It is for people whose surgery is considered high risk for developing that complication.
LilleAges 18 years+ - NCT05141253RecruitingEarly Phase 1
Trial of RD133 for mesothelin-positive tumors after prior treatment
This early-stage trial tests whether RD133 can be safe and effective for people whose solid tumors have a high “mesothelin” marker and that have not responded to at least two standard treatments. If you qualify, you’ll be checked closely for side effects and whether the tumor responds.
Wuhan, HubeiAges 18 years+ - NCT05155189RecruitingPhase 1
Armored CAR-T treatment for advanced liver cancer
This Phase 1 trial tests the safety and early signs of effectiveness of an “armored” CAR-T cell therapy (C-CAR031) for advanced hepatocellular carcinoma (liver cancer). It may help by teaching the body’s immune cells to better recognize and attack the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT05171894RecruitingPhase 2
Test of lower light dose for port-wine birthmarks
This Phase 2 study tests whether using a lower light dose during a treatment called Hemoporfin PDT can safely shrink port-wine birthmarks (PWB). It aims to find a dose that works well while causing fewer side effects.
Irvine, CaliforniaAges 18–75 - NCT05183646RecruitingPhase 3
DMX-200 for FSGS in people taking an ARB medicine
This Phase 3 trial studies whether DMX-200 is safer and works better than placebo for people with FSGS who are already on (or can switch to) an ARB blood-pressure/kidney-protection medicine. It also looks at side effects over a long follow-up period.
Birmingham, AlabamaAges 12–80 - NCT05184335RecruitingPhase 3
Brilaroxazine for adults with schizophrenia
This study tests whether brilaroxazine works and is safe for people with schizophrenia. It mainly aims to help people whose symptoms are still present despite prior treatment, while excluding those with certain other diagnoses or substance/drug issues.
Phoenix, ArizonaAges 18–65 - NCT05189054Recruiting
Radiation retreatment for very central chest tumors
This trial tests a focused form of radiation (SBRT) to treat tumors in the very center of the chest that have already been treated with radiation before. It aims to check safety and whether the tumor can be controlled without causing unacceptable side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT05190991RecruitingPhase 2
RPH-104 to prevent repeat fevers in colchicine-resistant FMF
This Phase 2 study tests whether RPH-104 can help prevent recurrent fever attacks in adults with Familial Mediterranean Fever (FMF) who cannot tolerate colchicine or whose disease does not respond to it. Participants may receive the medicine at the clinic or learn to give it as a self-injection, depending on what fits your situation.
YerevanAges 18–80 - NCT05199909RecruitingPhase 2
Testing zanubrutinib for antiphospholipid syndrome with low platelets
This Phase 2 study tests zanubrutinib, a medicine for the immune system, to treat antiphospholipid syndrome when it causes very low platelet counts. It looks at safety and whether it can improve blood clotting problems and low platelets when prior steroid treatment didn’t work well.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05219617RecruitingPhase 3
Carisbamate for frequent drop seizures in Lennox-Gastaut
This Phase 3 study tests whether carisbamate can reduce drop seizures in people with Lennox-Gastaut syndrome (LGS). It also checks whether the treatment is safe when added to existing seizure medicines.
Palo Alto, CaliforniaAges 4–55 - NCT05254327RecruitingPhase 2
Radiation plus or minus BMX-001 for advanced rectal cancer
This Phase 2 study tests two different ways of giving radiation before surgery for locally advanced rectal cancer, with or without an added study drug called BMX-001. It aims to see whether the shorter/longer radiation plans and BMX-001 improve cancer control and are safe.
Lexington, KentuckyAges 18 years+ - NCT05264753Recruiting
Follow-up study for a device that closes an abnormal heart blood vessel
This study checks how well and how safely the Occlutech PDA Occluder works over time to close a patent ductus arteriosus (PDA). You may be considered if your PDA can be treated with this non-surgical device and you can return for follow-up visits.
MontrealAges Any age - NCT05268289RecruitingPhase 2
Trial for lupus kidney inflammation using LNP023
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
Phoenix, ArizonaAges 18–100 - NCT05269459RecruitingPhase 2
CBD for PTSD symptoms in adults
This Phase 2 study tests whether cannabidiol (CBD) can safely reduce PTSD symptoms in adults. You may be eligible if you have a current PTSD diagnosis and can follow the study steps for the full time.
Omaha, NebraskaAges 21–65 - NCT05282108Recruiting
Generic imatinib vs Glivec for newly diagnosed CML
This trial studies whether a generic version of imatinib (Carcemia®) works as well and is as safe as Glivec® in real-life care for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). It may help confirm that the generic option is effective for controlling the disease.
CairoAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,831 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.